Carisma Therapeutics Inc (CARM) News

Form 8-K - Current report

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders PR Newswire PHILADELPHIA, June...

CARMILA: Information Concerning the Total Number of Voting Rights and Share

provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de...

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference PR Newswire PHILADELPHIA...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR...

Carmila: Réduction des moyens du contrat de liquidité

Regulatory News: Par contrat en date du 3 novembre 2023 la société Carmila SA (Paris:CARM) a confié à Kepler Cheuvreux la mise en œuvre d’un...

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of...

CARMILA: Information Concerning the Total Number of Voting Rights and Share

provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de...